SCHEMBL4001668

SCHEMBL4001668

CCCC(C)C(C)CCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.52
GABRD O14764 2/20 0.52
GABRA1 P14867 2/20 0.52
GABRB1 P18505 2/20 0.52
GABRG2 P18507 2/20 0.52
GABRB3 P28472 2/20 0.52
GABRA5 P31644 2/20 0.52
GABRA3 P34903 2/20 0.52
GABRA2 P47869 2/20 0.52
GABRB2 P47870 2/20 0.52
GABRA4 P48169 2/20 0.52
GABRE P78334 2/20 0.52
GABRA6 Q16445 2/20 0.52
GABRG1 Q8N1C3 2/20 0.52
GABRG3 Q99928 2/20 0.52
GABRQ Q9UN88 2/20 0.52
CYP1A2 P05177 1/20 0.52
ALDH1A1 P00352 3/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC2 Q92769 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14360718 0.89 GABRP (0.62) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5283650 0.86 AKR1B1 (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15062487 0.85 GABRP (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2137150 0.82 CYP1A2 (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL28501128 0.82 GABRP (0.45) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL12355559 0.81 ALDH1A1 (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL13196687 0.81 GABRP (0.43) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8835151 0.80 HDAC1 (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1198338 0.80 MAPT (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL14360827 0.80 GABRP (0.52) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4641061-A1 OIL-WELL METAL PIPE NIPPON STEEL CORPORATION (JP) 2025-10-29 EP claimed
WO-2024135464-A1 OIL-WELL METAL PIPE 日本製鉄株式会社 2024-06-27 WO claimed
EP-4641061-A1 OIL-WELL METAL PIPE NIPPON STEEL CORPORATION (JP) 2025-10-29 EP disclosed
US-20240408180-A1 IONIC LIQUIDS FOR DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-12-12 US disclosed
EP-4412587-A1 IONIC LIQUIDS FOR DRUG DELIVERY President And Fellows Of Harvard College (US) 2024-08-14 EP disclosed
CN-118382429-A Ionic liquids for drug delivery 哈佛大学校长及研究员协会 2024-07-23 CN disclosed
WO-2024135464-A1 OIL-WELL METAL PIPE 日本製鉄株式会社 2024-06-27 WO disclosed
WO-2023059846-A1 IONIC LIQUIDS FOR DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-04-13 WO disclosed
WO-2022271537-A1 COMPOSITIONS AND METHODS RELATING TO INJECTABLE MICROEMULSIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-12-29 WO disclosed
US-20220257767-A1 IONIC LIQUIDS FOR DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-08-18 US disclosed
EP-3946261-A1 IONIC LIQUIDS FOR DRUG DELIVERY President And Fellows Of Harvard College (US) 2022-02-09 EP disclosed
CN-113939273-A Ionic liquids for drug delivery 哈佛大学校长及研究员协会 2022-01-14 CN disclosed
WO-2020205409-A1 IONIC LIQUIDS FOR DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-10-08 WO disclosed
US-10632088-B2 Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria NORTHWESTERN UNIVERSITY (US) 2020-04-28 US disclosed
US-20180098952-A1 INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA NORTHWESTERN UNIVERSITY (US) 2018-04-12 US disclosed
EP-2069302-A1 SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS Pfizer Inc. (US) 2009-06-17 EP disclosed
WO-2008032204-A1 SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180098952-A1 INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA OAT, OTC, ABAT GABRP 148/4885GABRD 106/4885GABRA1 81/4885
US-10632088-B2 Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria OAT, OTC, ABAT GABRP 148/4885GABRD 106/4885GABRA1 81/4885
US-20220257767-A1 IONIC LIQUIDS FOR DRUG DELIVERY SLCO4C1, SLC47A1, ABCB11 GABRP 3164/4885GABRD 3694/4885GABRA1 3719/4885
US-20240408180-A1 IONIC LIQUIDS FOR DRUG DELIVERY SLCO4C1, SLC47A1, ABCB11 GABRP 3164/4885GABRD 3694/4885GABRA1 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.